On April 15, 2024, RenovoRx, Inc. closed the transaction. The company will issue securities pursuant to exemption provided under Regulation D from 172 investors. The company paid $1,280,937 as sales commissions in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 USD | +7.81% | +18.85% | -36.68% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.68% | 34.73M | |
+3.91% | 109B | |
+10.87% | 105B | |
-0.20% | 22.25B | |
-13.14% | 22.09B | |
-7.75% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. announced that it has received $11.136652 million in funding